Peptide News Digest

#Evaxion

2 stories

Clinical Trials · View digest

Evaxion to Present New Immune Data for Its AI-Designed Personalized Peptide Vaccine EVX-01 Plus Keytruda in Melanoma at SITC 2026

Evaxion said on Friday, October 2, 2026 that it will present new immune data from its Phase 2 trial of EVX-01, a personalized, AI-designed peptide cancer vaccine given with Merck's Keytruda (pembrolizumab) to 16 patients with advanced melanoma, at the Society for Immunotherapy of Cancer meeting in Phoenix, with an oral presentation on November 6. Previously reported two-year results showed objective responses in 12 of 16 patients (75%), including four complete responses, and tumor-specific immune responses to 86% of the vaccine's neoantigen targets. Each patient receives a vaccine designed and manufactured from their own tumor's biology.

Clinical Trials · View digest

Evaxion EVX-01 Personalized Peptide Vaccine Achieves 75% ORR at 2 Years in Metastatic Melanoma

Evaxion's AI-designed personalized neoantigen peptide vaccine EVX-01 combined with Keytruda produced a 75% objective response rate at 2 years in advanced melanoma patients, with 86% of vaccine targets triggering de novo T-cell responses. Data were presented April 22 at AACR 2026; 3-year follow-up expected in H2 2026. The 86% target-hit rate demonstrates AI-designed peptide neoantigen selection maturing for cancer vaccines.